Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Saved in:
| Title: | Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen. |
|---|---|
| Authors: | Brown K; Janssen Scientific Affairs, LLC, Titusville, NJ, USA., Thomas D; Janssen Research & Development, LLC, Titusville, NJ, USA., McKenney K; Janssen Research & Development, LLC, Titusville, NJ, USA., Reeder M; Janssen Research & Development, LLC, Raritan, NJ, USA., Simonson RB; Janssen Scientific Affairs, LLC, Titusville, NJ, USA., Bicer C; BICER Consulting & Research, Antwerp, Belgium., Nettles RE; Janssen Scientific Affairs, LLC, Titusville, NJ, USA., Crauwels H; Janssen Research & Development, Beerse, Belgium. |
| Source: | Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 May; Vol. 8 (4), pp. 541-548. Date of Electronic Publication: 2018 Dec 03. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2160-7648 (Electronic) Linking ISSN: 2160763X NLM ISO Abbreviation: Clin Pharmacol Drug Dev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2160-7648 |
|---|---|
| DOI: | 10.1002/cpdd.632 |
